REG - OptiBiotix Health - Launch of Daily Nouri FeelFull product in America

OptiBiotix HealthAnnouncement

18/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250218:nRSR4226Xa&default-theme=true

RNS Number : 4226X  OptiBiotix Health PLC  18 February 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of Daily Nouri FeelFull product in America

SlimBiome® containing finished products

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces the launch of FeelFull, containing SlimBiome®, by Daily Nouri
("Nouri") in the United States of America (USA).

 

Daily Nouri is a well-known brand in the USA known for its science-backed,
clinically supported probiotic and prebiotic solutions which impact on gut
health. Nouri sell their products in their online store (www.
(http://www.dailynouri.com) dailynouri.com (http://www.dailynouri.com) ), on
Amazon, and in stores of some of the largest retailers in the USA such as
Walmart and Albertsons.

 

FeelFull is a prebiotic lemonade drink containing SlimBiome® formulated by
Nouri which has been created "to help consumers regulate appetite, curb
cravings, and support metabolic health by increasing viscosity in the stomach,
slowing gastric emptying, and stabilising blood sugar levels to create a
feeling of fullness and help satiate overall desire for food intake.". The
lemonade is a powdered drink in portable stick packs which can be mixed with
water with 'on pack' health claims which state daily use supports 'reduced
appetite and cravings' and a 'feeling of fullness' derived from OptiBiotix's
multiple clinical studies. 'On pack' health claims are important in
differentiating products in the weight management market and are an area of
high consumer interest since the launch of the appetite reducing anti-obesity
drugs. Nouri forecast a requirement for ten metric tons of SlimBiome® in year
one.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "Nouri is a well-known and
respected brand in the USA with an online presence and products in major
retailers like Walmart and Albertsons, the second largest supermarket in the
USA. This initial launch is for a FeelFull lemonade product with the potential
for further products within the FeelFull range depending on sales progress.
This launch represents a step forward for the Company's products in the USA
market and the first of a number of launches planned with partners across the
USA.

 

"With recent product launches in India (Morepen, Amazon), China, large parts
of Asia (Philippines, Vietnam, Indonesia, Malysia and Thailand) and now the
USA, the Company is growing its brand presence in international markets around
the world. This global approach, whilst taking longer than a single market
approach but with greater upside, has the potential to create multiple revenue
streams and build a substantial global business in the years ahead."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                         www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)          Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)           Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                               Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLBRGDDSSBDGUR